Follow-The-Filings

Security · featured owners

GLUE Monte Rosa Therapeutics Inc.

COM Equity as of 2026 Q2 among managers we track

  • 2 Owners
  • Max 1.6%
  • $25M
  • 2 new

Who owns this now

Largest portfolio weights among featured holders · max 1.6% (James Silverman - Opaleye...) · not free-float ownership

  1. James Silverman new 1.6%
  2. Stanley Druckenmiller new 0.14%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
James Silverman - Opaleye Management 2026 Q2 1.6% New 1.6% 745,000 $18M history
Stanley Druckenmiller - Duquesne Family Office 2026 Q2 0.14% New 0.14% 297,600 $7M history

2 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue — $75.62M $123.67M
Net income -$135.35M -$72.7M -$38.63M
Net margin * — -96.1% -31.2%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $236.21M $377.44M $393.18M
Total non-current assets * $67.54M $61.29M $55.47M
Total assets $303.76M $438.73M $448.66M
Total current liabilities $46.59M $156.95M $64.21M
Total non-current liabilities * $77.91M $58.85M $151.39M
Total equity $179.25M $222.94M $233.06M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$43.8M $42M -$22.8M
Cash from investing $88.8M -$44.45M -$101.83M
Cash from financing $27.49M $98.89M $30.35M
Net change in cash $72.49M $96.44M -$94.28M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders